OVERVIEW
Cytomegalovirus (CMV) is often referred to as the “troll of transplantation” because it lurks quietly, waiting to emerge and complicate the clinical course of organ transplant patients. Join our infectious diseases experts, Drs. Humar, Razonable, and Silveira, as well as an experienced patient with CMV for this live-streamed event aimed at “taming the troll.” The panel will discuss guideline-based CMV treatment strategies and how to approach refractory and drug-resistant CMV after solid organ transplantation (SOT), including a new therapeutic option. Prepare to ask your challenging CMV in SOT questions to the panel at the end of the discussion.
GOAL STATEMENT
The goal of this activity is to provide clinicians with the clinical tools necessary to identify and manage treatment-refractory and drug-resistant CMV in patients after solid organ transplantation (SOT). A panel of infectious diseases experts will review current CMV treatment guidelines, discuss antiviral resistance testing, and provide insights for management with a new antiviral therapeutic option. An experienced patient with CMV will provide important practical take-aways for clinicians to use with their own SOT patients.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be better able to: [LIST][ITEM]Employ current cytomegalovirus (CMV) treatment guidelines for the use of antiviral therapies and management of their adverse effects [ITEM]Identify treatment-refractory and drug-resistant CMV by correctly interpreting antiviral resistance testing results [ITEM] Select transplant patients who will benefit from the efficacy and reduced toxicity of new CMV therapy [/LIST]
ACCREDITATION STATEMENT
In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
[bold]For Physicians[/bold] RMEI Medical Education, LLC designates this live activity for a maximum of 1.0 [italic]AMA PRA Category 1 Credits[/italic]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. [bold]For Pharmacists[/bold] RMEI Medical Education, LLC designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008290-0000-23-004-L01-P) Type of Activity: Knowledge
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI will disclose to learners the presence or absence of relevant financial relationships for all persons in control of content before the learner engages in the education.
Supported by an educational grant from Takeda Pharmaceuticals, U.S.A., Inc.
Provided by RMEI Medical Education, LLC.
